QurieGen’s Post

AI can beat grandmasters at chess and outwit the world’s best at Go – but is it better than humans at coming up with new drugs? We speak to Dr Dave H. (Exscientia Chief Scientific Officer and Interim CEO) and Dr Alex Zhavoronkov (Insilico Medicine Founder and CEO) about their work revolutionising drug discovery: https://hubs.la/Q02vkX_q0 #artificialintelligence #AI #drugdiscovery #bioinformatics #computationalbiology #pharma #biotech Also mentioned: Sumitomo Pharma Co., Ltd., Sanofi, Bristol Myers Squibb, Merck Group, Bill & Melinda Gates Foundation, Relay Therapeutics, Nimbus Therapeutics, Healx, Google DeepMind

If you haven't heard the huge news already, Recursion announced its plan to acquire its smaller peer, Exscientia, for $688 million. This acquisition is part of Recursion's strategy to strengthen its position in the AI-powered drug discovery space. Exscientia, known for its expertise in using AI to design and develop new drugs, will complement Recursion's existing capabilities, potentially accelerating the development of novel therapies. This huge deal highlights the growing importance of AI integration in the pharmaceutical industry, as companies look to leverage technology to speed up drug discovery and reduce costs. #computationalchemistry #drugdiscovery #ai #machinelearning #biotechacquisition

🌟 Gilead & GEM Genesis: Unlocking New Frontiers with AI 🌟 Exciting developments are underway as Gilead partners with GEM Genesis in a $35M pact to leverage GEM’s AI-powered drug discovery platform. This collaboration marks a bold step forward in AI-driven drug development, potentially accelerating the discovery of innovative therapies in areas of unmet medical need. AI platforms like Genesis are revolutionizing how we approach drug discovery, offering faster and more precise identification of new therapeutic candidates. By combining Gilead's deep expertise with GEM’s cutting-edge technology, this collaboration has the potential to push the boundaries of medical research. As AI continues to transform the biotech and pharma landscape, partnerships like these will be crucial in delivering breakthrough treatments to patients faster than ever. https://lnkd.in/e-hZkhtB #AIinHealthcare #DrugDiscovery #BiotechInnovation #AI #Pharma #Gilead #PrecisionMedicine #MedTech

🌟 Gilead & GEM Genesis: Unlocking New Frontiers with AI 🌟 Exciting developments are underway as Gilead partners with GEM Genesis in a $35M pact to leverage GEM’s AI-powered drug discovery platform. This collaboration marks a bold step forward in AI-driven drug development, potentially accelerating the discovery of innovative therapies in areas of unmet medical need. AI platforms like Genesis are revolutionizing how we approach drug discovery, offering faster and more precise identification of new therapeutic candidates. By combining Gilead's deep expertise with GEM’s cutting-edge technology, this collaboration has the potential to push the boundaries of medical research. As AI continues to transform the biotech and pharma landscape, partnerships like these will be crucial in delivering breakthrough treatments to patients faster than ever. https://lnkd.in/e-hZkhtB #AIinHealthcare #DrugDiscovery #BiotechInnovation #AI #Pharma #Gilead #PrecisionMedicine #MedTech

Gilead Sciences partners with Genesis Therapeutics in a $35M collaboration to accelerate AI-driven drug discovery    Genesis’ innovative GEMS AI platform continues to capture attention, now attracting Gilead Sciences to its growing list of partners. With this new collaboration, Gilead is investing $35M upfront for AI-based drug discovery on three undisclosed targets. This marks Genesis’ third major pharma partnership, following previous deals with Genentech and Eli Lilly. Together, Gilead and Genesis aim to revolutionize the discovery of treatments for difficult protein targets by harnessing the power of generative AI.  Did you know there is also AI for the clinical development process? By automatically harnessing, consolidating and reconciling study data, while a study is ongoing, Prevail InfoWorks delivers predictive analytics, confirmatory clinical observations early, and the fastest trend analyses and reporting. To learn more about this and other technologies in clinical development, access Prevail InfoWorks’ proven track record here: https://lnkd.in/e2wWMMej "Needs are diverse and ever-changing, and that’s why we are committed to staying ahead of the curve, anticipating trends, and delivering solutions that exceed expectations." stated Jack Houriet, CEO of Prevail InfoWorks. How do you think AI is transforming the future of our life sciences industry and will it overcome the inefficiencies and burdensome processes? Read more in the comment section. #DrugDiscovery #Biotechnology #GileadSciences #GenesisTherapeutics #PharmaInnovation #HealthcareAI #ClinicalResearch #ArtificialIntelligence #RDCollaboration

The journey of a new therapeutic drug coming to the marketplace is a complex and lengthy process that typically involves several key stages. Learn about drug discovery and preclinical research: https://lnkd.in/gCMXwaHy #drugdiscovery

Connect with other Founders: https://lnkd.in/g2-KKmea Alphabet's Isomorphic Labs, led by CEO Sergei Yakneen, an AI-driven drug discovery startup, has secured deals with Eli Lilly and Novartis totaling nearly $3 billion. These collaborations aim to enhance Google DeepMind's AlphaFold AI technology, known for predicting protein structures in drug discovery. Eli Lilly's deal is valued at up to $1.5 billion, and Novartis's at up to $1.4 billion. Isomorphic's AI platform will be used for identifying and developing novel drug candidates, showcasing the potential to revolutionize the traditionally slow and expensive pharmaceutical development process. The timing of these deals, just before the J.P. Morgan Healthcare Conference, suggests Isomorphic's strategic move to solidify its position in drug discovery. Read more at: https://lnkd.in/gpmwjFjS

The journey of a new therapeutic drug coming to the marketplace is a complex and lengthy process that typically involves several key stages. Learn about drug discovery and preclinical research: https://lnkd.in/gCMXwaHy #drugdiscovery #preclinicalresearch

Aqemia Secures $32.5 Million for AI-Powered Drug Discovery Platform 💊. Aqemia has successfully raised $32.5 million in funding for its generative AI-powered drug discovery platform. The company intends to utilize this funding to expand its pipeline of drug discovery projects and assets. Aqemia's platform leverages artificial intelligence to identify and design drug candidates, thereby revolutionizing the drug discovery process. This substantial investment underscores the growing interest and confidence in AI-driven approaches within the pharmaceutical industry, signaling significant advancements in drug development and personalized medicine. #pharmaceuticals #drugdiscovery #artificialintelligence

We are thrilled to announce that Zafrens has come out of stealth mode with $23M in financing to transform drug discovery with our Z-Screen platform. The financing will help accelerate our internal discovery efforts and empower us to expand our offerings to pharma & biotech partners. Z-Screen offers unprecedented scale (1000x compared to traditional HTS setup) and unmatched insights with functional and molecular readouts for every condition. The platform is built from ground-up with flexibility to seamlessly screen across multiple modalities (small molecules, large molecules (BCR/TCR), and cells (CAR-T)) with the same fidelity. We have been crafting this technology for over a year and excited to finally unleash its potential collaborating with visionary partners to unlock hard-to-screen targets. #drugdiscovery#pharma#biotech#financing#TCR#smallmolecule#bispecific#antibody#biologics#CAR-T#cell#therapy https://lnkd.in/gHzbAxRM